Pfizer (NY:<a title="Quote for Pfizer" href="https://markets.financialcontent.com/buffnews/quote?Symbol=NY%3APFE">PFE )

In a pivotal moment for the consumer health landscape, Kenvue (NYSE: KVUE) has reported a robust set of fourth-quarter results for 2025, signaling a successful turnaround and strategic resilience just...

Kenvue Defies Market Headwinds with Q4 Earnings Beat as Kimberly-Clark Merger Looms

February 23, 2026

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other...

Topics Earnings Economy World Trade

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

February 23, 2026

From Pfizer Inc.

Via Business Wire

February 22, 2026

Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position ↗

February 22, 2026

Celcuity develops targeted cancer therapies and diagnostic platforms, with a focus on advancing precision medicine in oncology.

There are several solid prospects to choose from right now, but there's a reason I can't get these particular names out of my head.

My 5 Favorite Dividend Stocks to Buy Right Now ↗

February 22, 2026

Is Pfizer's 6% yield a rare opportunity hiding in plain sight, or are investors overlooking a major risk that could reshape its future?

Massive News: Pfizer's 6% Dividend Could Be Safer Than You Think ↗

February 21, 2026

Pfizer is playing catch-up in the GLP-1 drug space, but the drugmaker has a long history of success.

Is Pfizer Stock an Underrated Healthcare Investment Play? ↗

February 20, 2026

Explore the S&P500 index on Friday and find out which stocks are the most active in today's session. ↗

Topics Intellectual Property

February 20, 2026

Via Chartmill

Is Pfizer Stock the Only Big Pharma Name I'd Buy and Hold Through Any Market Crash? ↗

February 20, 2026

New products are already generating growth.

Eli Lilly is leading the pack in the GLP-1 weight-loss drug market, but this good news won't last forever.

Topics Intellectual Property

Warning: This Skyrocketing Stock Has a Hidden Risk ↗

February 19, 2026

Pfizer’s BRAFTOVI BREAKWATER Trial Delivers Landmark Survival Gains in Colorectal Cancer

Topics Intellectual Property

February 19, 2026

NEW YORK — Pfizer Inc. (NYSE: PFE) has announced breakthrough results from its Phase 3 BREAKWATER clinical trial, demonstrating that its BRAFTOVI (encorafenib) regimen significantly improves both...

If you are looking for high-yield stocks, these two turnaround stories offer yield and green shoots, suggesting better times are ahead.

Top High-Yield Stocks to Double Up on Right Now ↗

February 19, 2026

Nasdaq, S&P 500 Futures Edge Higher, Trump Speech In Focus: Why WMT, META, IBRX, MSFT, EBAY Are On Traders' Radar Today ↗

February 19, 2026

Data from Stocktwits indicated retail sentiment towards SPY and QQQ cooled to neutral.

Via Stocktwits

Topics ETFs Economy Government

2 Large-Cap Stocks on Our Watchlist and 1 We Brush Off

February 18, 2026

Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an...

Optimism also grew around FDA momentum for its palmoplantar pustulosis drug ahead of MoonLake’s Feb. 23 investor day.

MoonLake Stock Soars As Biotech Fund Reloads, Takeover Chatter Ignites ↗

February 17, 2026

Via Stocktwits

1 Reason I'd Buy Eli Lilly Stock and Never Sell ↗

February 17, 2026

A robust pipeline is essential for a buy-and-hold pharmaceutical stock.

Pfizer's Braftovi combo improves survival in advanced colorectal cancer trial.

Topics Intellectual Property

Pfizer's Cancer Drug Combo Shows Strong Results In Key Colorecatal Cancer Trial ↗

February 17, 2026

Via Benzinga

Moderna’s mRNA Renaissance: Navigating Volatility and the Post-Pandemic Pipeline

February 17, 2026

As of February 17, 2026, Moderna, Inc. (NASDAQ:MRNA) finds itself at a pivotal crossroads in its corporate evolution. Long defined by its meteoric rise during the COVID-19 pandemic, the Cambridge-based...

Via Finterra

Topics Economy Intellectual Property

Pfizer’s BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer

February 17, 2026

From Pfizer Inc.

Via Business Wire

2 S&P 500 Stocks to Research Further and 1 We Question

February 16, 2026

While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural...

Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built their fortunes by purchasing wonderful...

Topics Stocks

2 Value Stocks Worth Your Attention and 1 We Brush Off

February 16, 2026

The Great Inflation Thaw: US Price Pressures Hit Five-Year Low as Federal Reserve Eyes 2026 Pivot

February 16, 2026

The United States economy reached a long-awaited milestone this week as the Bureau of Labor Statistics reported that headline inflation fell to 2.4% in January 2026, with the core Consumer Price Index...

As the oncology community prepares to descend upon San Francisco for the 2026 ASCO Genitourinary (GU) Cancers Symposium from February 26–28, investors and clinicians alike are bracing for data that...

Topics Artificial Intelligence Bonds Economy

ASCO GU 2026: Merck and Protara Poised to Disrupt Bladder and Kidney Cancer Standards

February 16, 2026

The S&P 500 (^GSPC) is packed with companies that have built dominant market positions, making it a core index for investors. A select few continue to innovate and expand, setting themselves up for...

Topics Intellectual Property

3 S&P 500 Stocks Worth Investigating

February 15, 2026

Eli Lilly continues to pursue smart acquisitions for the long term.

Topics Stocks

What Is One of the Best Pharmaceutical Stocks to Own for the Next 10 Years? ↗

February 14, 2026

Moderna Shares Surge as Aggressive Cost-Cutting and Post-Pandemic Pivot Take Hold in Q4 Results

Topics Intellectual Property

February 13, 2026

Moderna Inc. (NASDAQ: MRNA) shares jumped 8% in early trading on February 13, 2026, after the biotechnology pioneer reported fourth-quarter 2025 financial results that exceeded Wall Street’s...

Hospitals Stand Tall: Healthcare Sector Becomes Safe Haven Amid "Warsh Shock" and Tech Volatility

Topics Earnings

February 13, 2026

In a day defined by sharp reversals and a fundamental recalibration of market leadership, the healthcare sector emerged as the primary beneficiary of a massive capital rotation on February 13, 2026....

The Great 2026 Divergence: Tech Titans Rise on AI Execution While Healthcare Reaps a Regulatory Whirlwind

Topics Artificial Intelligence Earnings Economy

February 13, 2026

As the opening bell rang on February 13, 2026, the divergence between the U.S. technology and healthcare sectors reached a historic fever pitch, signaling a fundamental shift in how markets price...